Bergstrom, Erik N.
Luebeck, Jens
Petljak, Mia
Khandekar, Azhar
Barnes, Mark http://orcid.org/0000-0002-5650-780X
Zhang, Tongwu http://orcid.org/0000-0003-2124-2706
Steele, Christopher D.
Pillay, Nischalan http://orcid.org/0000-0003-0579-4105
Landi, Maria Teresa http://orcid.org/0000-0003-4507-329X
Bafna, Vineet http://orcid.org/0000-0002-5810-6241
Mischel, Paul S. http://orcid.org/0000-0002-4560-2211
Harris, Reuben S. http://orcid.org/0000-0002-9034-9112
Alexandrov, Ludmil B. http://orcid.org/0000-0003-3596-4515
Article History
Received: 27 May 2021
Accepted: 4 January 2022
First Online: 9 February 2022
Competing interests
: M.P. is a shareholder in Vertex Pharmaceuticals. V.B. is a co-founder, consultant and Scientific Advisory Board member of, and has equity interest in, Boundless Bio, and Abterra. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. E.N.B. and L.B.A. declare filing a provisional patent application for using clustered mutations as clinical prognostic biomarkers in cancer. P.S.M. is a co-founder of Boundless Bio. He has equity in the company and he chairs the Scientific Advisory Board, for which he is compensated. L.B.A. is an inventor on US patent no. 10,776,718 for source identification by non-negative matrix factorization. All other authors declare no competing interests.